Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(20 sites)
United States
University of Alabama at Birmingham, Birmingham, Alabama City of Hope, Duarte, California University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center, Orange, California Stanford Cancer Institute, Palo Alto, California Yale Cancer Center, New Haven, Connecticut Winship Cancer Institute of Emory University, Atlanta, Georgia Dana Farber Cancer Institute, Boston, Massachusetts Karmanos Cancer Institute, Detroit, Michigan Washington University School of Medicine in St. Louis, St Louis, Missouri Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey Roswell Park Cancer Institute, Buffalo, New York New York-Presbyterian/Columbia University Irving Medical Center - Herbert Irving Comprehensive Cancer Center (HICCC), New York, New York Memorial Sloan-Kettering Cancer Center, New York, New York Novant Health Presbyterian Medical Center, Charlotte, North Carolina Cleveland Clinic, Cleveland, Ohio Oregon Health & Science University, Portland, Oregon University of Pennsylvania - Perelman Center, Philadelphia, Pennsylvania Vanderbilt University - Ingram Cancer Center, Nashville, Tennessee UT Southwestern Medical Center, Dallas, Texas MD Anderson, Houston, Texas